Geneoscopy: Funding, Investors & Team (Sep 2026)
Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently, there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasive colonoscopy. Geneoscopy is changing that. It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications.
Geneoscopy has raised $210M across 2 funding rounds on record, the most recent a Series C of $105M announced in Jan 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Geneoscopy Company Profile and Key Stats
Latest funding round on record: Jan 2025.
Geneoscopy Funding Rounds
Geneoscopy raised $105M in a Series B announced in Nov 2021.
3.2 years later, a Series C of $105M was announced in Jan 2025.
Geneoscopy Founders and Leadership Team
Contact details for the Geneoscopy team: 1 of 1 has an email address on file.
Start 14-day free trial →Geneoscopy Funding Compared to Other Biotechnology Startups
Geneoscopy's latest round of $105M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Geneoscopy in Biotechnology and Saint Louis
Companies Similar to Geneoscopy
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Geneoscopy Funding FAQs
What does Geneoscopy do?
Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently, there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasive colonoscopy. Geneoscopy is changing that. It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications.
How much funding has Geneoscopy raised?
Geneoscopy has raised $210M across 2 rounds on record. The most recent is a Series C of $105M announced in Jan 2025.
When did Geneoscopy last raise funding?
Geneoscopy's most recent funding round on record is a Series C of $105M, announced in Jan 2025.
Who founded Geneoscopy?
FundedIQ lists Erica Barnell (Founder) at Geneoscopy.
Where is Geneoscopy headquartered?
Geneoscopy is based in Saint Louis, Missouri, United States.
How many employees does Geneoscopy have?
Geneoscopy is in the 11-50 employee band.
How does Geneoscopy's funding compare to other Biotechnology startups?
Geneoscopy's latest round of $105M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Geneoscopy Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Geneoscopy is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.